Clinical use of the domestic medicinal product Vazitren
pdf (Українська)

How to Cite

Suprun, E. (2020). Clinical use of the domestic medicinal product Vazitren. The Practitioner, (3-4), 16-20. Retrieved from https://plr.com.ua/index.php/journal/article/view/601

Abstract

The article gives a review of research results regarding clinical use of pentoxifylline to treat the following diseases: lower limb vessels arteriosclerosis obliterans and remittent limp, cerebral vessel disorders, diabetes, chronical renal disease, chronical cardiac disease, non-alcoholic fatty liver disease, rheumatoid arthritis and COVID‑19. Research analysis showed that pentoxifylline is an efficient product to treat both acute and chronical diseases. It is based not only on numerous clinical investigations but also on the product’s good tolerance, its versatile activity and economical availability.

pdf (Українська)

References

1. Инструкция препарата Вазитерен. Режим доступу: http://nikopharm.ua/ru/nproduct/pentoxifylline/
2. McCarty M.F., O’Keefe J.H., DiNicolantonio J.J. Pentoxifylline for vascular health: a brief review of the literature // Open. Heart. — 2016. — 3. — P. e000365.
3. Доказанная эффективность пентоксифиллина в лечении пациентов с цереброваскулярной патологией // Практична
ангіологія. — 2017. — 1 (76). — C. 42-46.
4. Barton M.H., Moore J.N., Norton N. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin // Am. J. Vet. Res. — 1997. — № 11 (9). — P. 1300-1307.
5. Кузнецова С.М., Петлицкая В.В. Клинические аспекты применения пентоксифиллина // The Journal of Neuroscience of B.M. Mankovskyi’. — 2018. — Т. 6, № 2.
6. Porter J.M., Cutler B.S., Lee B.Y., Reich T., Reichle F.A., Scogin J.T., Strandness D.E. Pentoxifylline Efficacy in the Treatment of Intermittent Claudication: Multicenter Controlled Double-Blind Trial With Objective Assessment of Chronic Occlusive Arterial Disease Patients.
7. Пентоксифиллин в лечении различных проявлений атеросклероза // Клінічна ангіологія. — 2007. — 5 (10). Режим доступу: https:// angiology.com.ua/ru-issue-article‑104
8. Colgan M.P., Dormandy J.A., Jones P.W. et al. Oxpentifylline treatment of venous ulcers of the leg // BMJ. — 1990. — 300. — Р. 972-975.
9. Кошкин В.М. Место Трентала® (пентоксифиллина) в программе лечения хронических облитерирующих заболеваний артерий конечностей и различных сосудистых осложнений. Режим доступу: https://cyberleninka.ru/article/n/mesto-trentala-pentoksifillinav-programme-lecheniya-hronicheskih-obliteriruyuschih-zabolevaniy-arteriy-konechnostey-i-razlichnyh
10. Moher D., Pham B., Ausejo M. et al. Pharmacological management of intermittent claudication: a metaanalysis of randomised trials // Drugs. — 2000. — № 59 (5). — P. 1057-1070.
11. Ward A. Pentoxifylline. A Review of its Pharmacodynamic and Pharmacokinetic Properties, and its Therapeutic Efficacy. Drug Evaluation Published: 23 October 2012.
12. Zhang M. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases // Exp. Clin. Cardiol. — 2004. — 9 (2). — P. 103-111.
13. Beyreder J. Treatment of Acute Cerebrovascular Insufficiency // Eur. Neurol. — 1983. — 22. — P. 116-123
14. Танашян М.М. Трентал при ишемических цереброваскулярных заболеваниях (обзор литературы). Режим доступу: http://www.mif-ua.com/archive/article/1885
15. Han S.J., Kim H.J. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study // Diabetol. Metab. Syndr. — 2015. — 7. — P. 64. Режим доступу: https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4546105/#:~: text=Pentoxifylline%20therapy%20reduced%20proteinuria%20and, treating%20diabetes%20and%20diabetic.

Downloads

Download data is not yet available.